Celgene price target raised to $92 from $78 at RW Baird

theflyonthewall.com

Baird raised its price target on Celgene citing its late stage pipeline and expectations for clarity on Revlimed's EU front-line approval status. Shares are Outperform rated.

View Comments

Recommended for You